Anti-A sensitization and complement activation
| A1 RBCs . | Sensitization* . | 6% albumin IgM . | Anti-human IgG . | Complement-mediated lysis† . | Anti-human C3b/d . |
|---|---|---|---|---|---|
| Untreated | Group O plasma | M+ | 2+ | No hemolysis | 0 |
| Pooled AB plasma | 0 | 0 | No hemolysis | 0 | |
| AET-treated | Group O plasma | W | 2+ | Hemolysis | M+ |
| Pooled AB plasma | 0 | 0 | No hemolysis | 0 |
| A1 RBCs . | Sensitization* . | 6% albumin IgM . | Anti-human IgG . | Complement-mediated lysis† . | Anti-human C3b/d . |
|---|---|---|---|---|---|
| Untreated | Group O plasma | M+ | 2+ | No hemolysis | 0 |
| Pooled AB plasma | 0 | 0 | No hemolysis | 0 | |
| AET-treated | Group O plasma | W | 2+ | Hemolysis | M+ |
| Pooled AB plasma | 0 | 0 | No hemolysis | 0 |
*Hemagglutination and hemolysis were scored according to Judd et al20 : 0, negative reaction, no agglutination; M+, agglutinates visible under microscope only; W, weak reaction, many tiny agglutinates; 2+, many small visible agglutinates.
Presence of hemolysis visualized after incubation with AB serum at 37°C for 60 min.